# LUNAR-2 (NCT06216301)

> LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06216301
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: NovoCure GmbH
- Conditions: Metastatic Non-small Cell Lung Cancer
- Interventions: NovoTTF-200T; Pembrolizumab; Platinum based chemotherapy
- Enrollment: 734
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 5
- Podcasts: 5
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=lunar-2-nct06216301

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06216301", "email": "<work email>"}; the inbox owner confirms by the emailed link.